Gender-Responsive Treatment for Women Offenders - 1

Recruiting in Palo Alto (17 mi)

Overseen by Michael Prendergast, Ph.D.

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of California, Los Angeles

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this study is to determine whether substance abuse treatment designed specifically for drug-dependent women offenders provides better outcomes than standard drug court treatment (mixed-gender programs).

Research Team

Michael Prendergast, Ph.D.

Principal Investigator

University of California, Los Angeles

Eligibility Criteria

Inclusion Criteria

Drug court participant

At least eighteen (18) years old

Have had no more than three prior non-violent, non-drug felony convictions

Treatment Details

Interventions

• Women-Only (Behavioral Intervention)

Participant Groups

Group I: Women-Only Experimental Treatment 1 Intervention

Substance abuse treatment program for women only

Group II: Mixed-Gender Active Control 1 Intervention

Substance abuse treatment program for both women and men

Who Is Running the Clinical Trial?

University of California, Los Angeles

Lead Sponsor

Trials

1,594

Recruited

10,430,000+

Dr. Thomas Rando

University of California, Los Angeles

Chief Medical Officer since 2023

MD from UCLA

Amir Naiberg

University of California, Los Angeles

Chief Executive Officer since 2024

JD from UCLA

National Institute on Drug Abuse (NIDA)

Collaborator

Trials

2,658

Recruited

3,409,000+

Dr. Nora Volkow

National Institute on Drug Abuse (NIDA)

Chief Executive Officer since 2003

MD from National Autonomous University of Mexico

Dr. Nora Volkow

National Institute on Drug Abuse (NIDA)

Chief Medical Officer since 2003

MD from National Autonomous University of Mexico